Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an…
By E. Van Cutsem, J. Tabernero, R. Lakomý, H. Prenen, J. Prausová, T. Macarulla, P. Ruff, G. V. van Hazel, V. Moiseyenko, D. Ferry and 5 more. Journal of Clinical Oncology, 2012
1,336 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/7dc116fbc57aee8afb3761f58dd7312660446b92
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “6 The efficacy and safety of AFL were confirmed in the VELOUR trial* [194].”
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “94) 1 [113]”
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, methodology): “FOLFIRI ± aflibercept VELOUR [27] Improvement in OS and PFS”
- Comprehensive review of targeted therapy for colorectal cancer (2020, result): “0032) than FOXFIRI plus placebo.(203) However, in terms of the first-line setting, as in the phase II AFFIRM trial, the combination of aflibercept with FOLFOX did not result in noticeable benefits in PFS or response rate, but did result in increased adverse event rates.”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Aflibercept, a recombinant fusion protein, that blocks the activity of VEGF-A, VEGF-B and placenta growth factor, improves survival, PFS and RR when combined in second line with FOLFIRI in oxaliplatin pre-treated patients, whether or not the patients were pre-treated with bevacizumab in first line [”
- Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence (2014, background): “…adjuvant traztuzumab for breast cancer (Romond et al, 2005)) and RCTs evaluating drugs with marginal effects and substantial toxicity (e.g., bevacizumab for advanced breast cancer (Miles et al, 2010; Robert et al, 2011), and aflibercept for advanced colorectal cancer (Van Cutsem et al, 2012)).”